Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

Nature Immunology

Volumn 6, Issue 9, 2005, Pages 928-937

  Oppenheim, David E ^a   Roberts, Scott J ^b   Clarke, Sarah L ^a   Filler, Renata ^b   Lewis, Julie M ^b   Tigelaar, Robert E ^b   Girardi, Michael ^b   Hayday, Adrian C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN RETINOIC ACID EARLY INDUCIBLE 1; TUMOR MARKER; UNCLASSIFIED DRUG; 7,12 DIMETHYLBENZ[A]ANTHRACENE; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; NATURAL KILLER CELL ACTIVATING RECEPTORS; PHORBOL 13 ACETATE 12 MYRISTATE; RAET1A PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; IN VIVO STUDY; INCIDENCE; INNATE IMMUNITY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; TRANSGENE; TUMOR IMMUNITY; TUMOR RESISTANCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARCINOMA; DISEASE PREDISPOSITION; DOWN REGULATION; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; NATURAL KILLER CELL; PAPILLOMA; PATHOLOGY; SKIN TUMOR; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOMA; CELL LINE, TUMOR; DISEASE SUSCEPTIBILITY; DOWN-REGULATION; FEMALE; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; LIGANDS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PAPILLOMA; RECEPTORS, IMMUNOLOGIC; SKIN NEOPLASMS; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE; TUMOR BURDEN;

EID: 24944500112     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni1239     Document Type: Article

References (50)

1. Janeway, C.A., Jr. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
2. Girardi, M. et al. Regulation of cutaneous malignancy by γδ T cells. Science 294, 605-609 (2001).
3. Cerwenka, A. et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12, 721-727 (2000).
4. Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N. & Raulet, D.H. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1, 119-126 (2000).
5. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
6. Jamieson, A.M. et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17, 19-29 (2002).
7. Pende, D. et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62, 6178-6186 (2002).
8. Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96, 6879-6884 (1999).
9. Vetter, C.S. et al. Expression of stress-induced MHC class I related chain molecules on human melanoma. J. Invest Dermatol. 118, 600-605 (2002).
10. Cerwenka, A., Baron, J.L. & Lanier, L.L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98, 11521-11526 (2001).
11. Diefenbach, A., Jensen, E.R., Jamieson, A.M. & Raulet, D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413, 165-171 (2001).
12. Teng, V. et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc. Natl. Acad. Sci. USA 99, 2977-2982 (2002).
13. Groh, V. et al. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2, 255-260 (2001).
14. Cosman, D. et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133 (2001).
15. Groh, V., Bruhl, A., El Gabalawy, H., Nelson, J.L. & Spies, T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100, 9452-9457 (2003).
16. Ogasawara, K. et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18, 41-51 (2003).
17. Hue, S. et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21, 367-377 (2004).
18. Meresse, B. et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21, 357-366 (2004).
19. Ogasawara, K. et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20, 757-767 (2004).
20. Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002).
21. Salih, H.R. et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102, 1389-1396 (2003).
22. Doubrovina, E.S. et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171, 6891-6899 (2003).
23. Derynck, R., Akhurst, R.J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129 (2001).
24. Castriconi, R. et al. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100, 4120-4125 (2003).
25. Lee, J.C., Lee, K.M., Kim, D.W. & Heo, D.S. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172, 7335-7340 (2004).
26. Carroll, J.M., Albers, K.M., Garlick, J.A., Harrington, R. & Taichman, L.B. Tissue- and stratum-specific expression of the human involucrin promoter in transgenic mice. Proc. Natl. Acad. Sci. USA 90, 10270-10274 (1993).
27. Kim, S. et al. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3, 523-528 (2002).
28. Diebold, S.S. et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424, 324-328 (2003).
29. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732-738 (2001).
30. Johansson, S.E., Hall, H., Bjorklund, J. & Hoglund, P. Broadly impaired NK cell function in non-obese diabetic mice is partially restored by NK cell activation in vivo and by IL-12/IL-18 in vitro. Int. Immunol. 16, 1-11 (2004).
31. Karre, K. NK cells, MHC class I molecules and the missing self. Scand. J. Immunol. 55, 221-228 (2002).
32. + T cells. Science 248, 1227-1230 (1990).
33. Kelly, A. et al. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 355, 641-644 (1992).
34. Millrain, M. et al. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J. Immunol. 167, 3756-3764 (2001).
35. Girardi, M. et al. Characterizing the protective component of the αβ T cell response to transplantable squamous cell carcinoma. J. Invest. Dermatol. 122, 699-706 (2004).
36. Salih, H.R., Rammensee, H.G. & Steinle, A. Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169, 4098-4102 (2002).
37. Smyth, M.J., Crowe, N.Y. & Godfrey,, D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459-463 (2001).
38. Kiessling, R. & Haller, O. Natural killer cells in the mouse: An alternative immune surveillance mechanism? Contemp. Top. Immunobiol. 8, 171-201 (1978).
39. Martin-Fontecha, A. et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for T(H)1 priming. Nat. Immunol. 5, 1260-1265 (2004).
40. + T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198, 747-755 (2003).
41. Gao, Y. et al. γδ T cells provide an early source of interferon γ in tumor immunity. J. Exp. Med. 198, 433-442 (2003).
42. Zuany-Amorim, C., Hastewell, J. & Walker, C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Discov. 1, 797-807 (2002).
43. + intraepithelial lymphocytes provided by serial analysis of gene expression (SAGE). Immunity 15, 419-434 (2001).
44. Carayannopoulos, L.N., Naideoko, O.V., Fremont, D.H. & Yokoyama, W.M. Cutting edge: Murine UL16-binding proteinAlike transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169, 4079-4083 (2002).
45. Stephens, H.A. MICA and MICB genes: Can the enigma of their polymorphism be resolved? Trends Immunol. 22, 378-385-(2001).
46. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991).
47. Mallick-Wood, C.A. et al. Conservation of T cell receptor conformation in epidermal γδ cells with disrupted primary V-γ gene usage. Science 279, 1729-1733 (1998).
48. Findly, R.C., Roberts, S.J. & Hayday, A.C. Dynamic response of murine gut intraepithelial T cells after infection by the coccidian parasite Eimeria. Eur. J. Immunol. 23, 2557-2564 (1993).
49. Masuda, H. et al. High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-"pan" RAE-1 antibody confer tumor susceptibility to NK cells. Biochem. Biophys. Res. Commun. 290, 140-145 (2002).
50. Coles, R.M., Mueller, S.N., Heath, W.R., Carbone, F.R. & Brooks, A.G. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J. Immunol. 168, 834-838 (2002).